Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Zuckerberg-Musk fight is on: Meta launches 'Twitter Killer' Threads app
Commentary: Why Artificial Intelligence Is Not So Scary. Carry On, OpenAI.
ChatGPT creator pulls AI detection tool due to 'low rate of accuracy'
Battery breakthrough brings ‘unprecedented performance’ to next-gen cells
VARK Inc. Raises Approximately One Billion Yen in the First Close of Series C
Skyflow Radically Simplifies Data Residency
Prism Labs Announces First-of-its-kind Mobile Bodymapping Technology with Integration into the Tempo Fitness Platform
Talkie Communications closes connectivity gap in Maryland with Adtran broadband platform